[Immunocorrective therapy of pyelonephritis in children].
A total of 40 children who suffered from acute or chronic pyelonephritis underwent immunological treatment with polypeptide drug tactivin. There was an evidence of clinical and laboratory improvement in 82.5 per cent of treated persons, first manifest in decreased proteinuria and normalized urinary sedimentation, and then in lower levels of bacteriuria due to the developing resistance to infectious agents. In 15 per cent of tactivin-treated children leukocyturia persisted though the disease progression was hindered. In the course of the treatment no side-effects were noted. In line with the stimulation of humoral immune response and activation of the complement system, tactivin administration evoked the competence of T-lymphocytes and potentiated the development of this link of immune system. As part of combined treatment the above preparation favourably affected the disease pathogenesis in children.
Kirillov
V I
VI
Zernov
N G
NG
Arion
V Ia
VIa
Tebloeva
L T
LT
Riabchikov
O P
OP
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007223:Infant; D008297:Male; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000276:immunology; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013949:Thymus Extracts / Q000009:adverse effects / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
Immunokorrigiruiushchaia terapiia pielonefrita u deteĭ.